| \(p_{orig}(\theta \mid y)\) and \(p_{scratch}(\theta \mid y,z)\) | \(p_{seq}(\theta \mid y,z)\) and \(p_{scratch}(\theta \mid y,z)\) | ||||
---|---|---|---|---|---|---|
Calibration target | CI overlap | Area overlap | SMD | CI overlap | Area overlap | SMD |
Pickhardt et al. [33]* | ||||||
% of detected adenomas | ||||||
 \(\le 5\)mm | 0.80 | 0.59 | 0.11 | 0.95 | 0.92 | 0.03 |
 \(6-9\)mm | 0.81 | 0.57 | 0.57 | 0.93 | 0.93 | 0.06 |
 \(\ge 10\)mm | 0.70 | 0.33 | 1.12 | 0.96 | 0.89 | 0.06 |
Corley et al. [3] | ||||||
 Prevalence, Men 50–54 | 0.62 | 0.25 | 1.39 | 0.91 | 0.76 | 0.21 |
 Prevalence, Men 55–59 | 0.63 | 0.28 | 1.29 | 0.92 | 0.75 | 0.21 |
 Prevalence, Men 60–54 | 0.69 | 0.33 | 1.11 | 0.92 | 0.77 | 0.21 |
 Prevalence, Men 65–69 | 0.75 | 0.41 | 0.89 | 0.92 | 0.79 | 0.19 |
 Prevalence, Men 70–74 | 0.84 | 0.53 | 0.62 | 0.93 | 0.81 | 0.17 |
 Prevalence, Men 75+ | 0.85 | 0.65 | 0.41 | 0.93 | 0.84 | 0.15 |
 Prevalence, Women 50–54 | 0.65 | 0.25 | 1.33 | 0.96 | 0.92 | 0.04 |
 Prevalence, Women 55–59 | 0.62 | 0.27 | 1.30 | 0.97 | 0.89 | 0.06 |
 Prevalence, Women 60–54 | 0.64 | 0.32 | 1.18 | 0.98 | 0.90 | 0.07 |
 Prevalence, Women 65–69 | 0.69 | 0.40 | 0.96 | 0.97 | 0.92 | 0.05 |
 Prevalence, Women 70–74 | 0.79 | 0.54 | 0.69 | 0.98 | 0.93 | 0.04 |
 Prevalence, Women 75+ | 0.86 | 0.68 | 0.45 | 1.00 | 0.95 | 0.02 |
Church [2] | ||||||
Pre-CRCs per 1000 lesions | ||||||
 [6, 10)mm | 0.65 | 0.30 | 1.39 | 0.98 | 0.92 | 0.08 |
 \(\ge 10\)mm | 0.00 | 0.00 | 6.70 | 0.97 | 0.91 | 0.09 |
Lieberman et al. [21]* | ||||||
Pre-CRCs per 1000 lesions | ||||||
 \(6-9\)mm | 0.90 | 0.73 | 0.36 | 0.96 | 0.93 | 0.07 |
 \(\ge 10\)mm | 0.00 | 0.00 | 7.68 | 0.98 | 0.92 | 0.03 |